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Controlled in vivo processing of scFv-MBP fusion proteins: Towards high level 
production of soluble and functional scFv-based biopharmaceuticals in bacterial 
system 
ABSTRACT 
In the past two decades, the bacterial expression of antibody fragments has shown 
great dependence in the rapid expansion and a key success in antibody engineering. 
Bacterial expression and antibody engineering provide a suitable means of creating antigen 
binding fragments for isolation, evaluation and production of antibody. In this study we 
succeeded to design specific primer for anti-HIV1-CA scFv, which was used in PCR 
amplification of anti-HIV1-CA scFv, MBP and vector pMXB10Hp24-6His. Subsequently, 
restriction enzyme analysis has been done using Nde1-R/Not1-F enzymes then the restricted 
insert and vector were ligated.  The constructed plasmid, pMXB10-MBP-TEV-scFv46 was 
transferred into E.Coli DH5-α competent cells.  Numerous positive clones were presented on 
the transformed plate and clones were randomly selected to be confirmed by colony PCR 
which showed the band for pMXB10-MBP-TEV-scFv46 clearly. The plasmid DNA was 
harvested, purified then transformed into NiCo21 (DE3), SHuffle (C3029) as competent 
cells for protein expression. The colony PCR was performed in order to confirm the 
presence of pMXB10-MBP-TEV-scFv46 clones in the transformant. Starter cultures were 
prepared in order to optimize expression of the protein of interest; (NiCo21-TEVEco and 
SHuffle-TEVEco) competent cells were used. Indeed, the expression of MBP-scFv-46 using 
XVIII 
 
NiCo21-TEVEco as competent cell was mainly present in the insoluble fraction. 
Immunoblot analysis with the anti-6His antibody revealed that none of MBP-scFv-46 
proteins was present in the soluble fraction.  However, Almost 90%-95% of MBP-scFv 
fusion protein has been cleaved by TEV protease using SHuffle-TEVEco. Immunoblot 
analysis also showed that almost 40% of scFv was present in the soluble fraction, which 
mean that we succeeded to develop novel system in order to achieve Controlled in vivo 
processing of MBP-scFv fusion proteins: Towards high level production of soluble scFv 
from E.Coli. 
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Kawalan dalam pemprosesan vivo scFv-MBP protein gabungan: Ke arah pengeluaran 
yang tinggi biofarmaseutikal berasaskan scFv larut dan berfungsi dalam sistem 
bakteria 
 
                                                                     ABSTRAK 
        Dalam dua dekad yang lalu, ungkapan bakteria serpihan antibodi telah ditunjukkan 
pergantungan yang besar dalam perkembangan pesat dan kejayaan utama dalam bidang 
kejuruteraan antibodi. Ungkapan bakteria dan kejuruteraan antibodi menyediakan satu cara 
yang sesuai mewujudkan antigen mengikat serpihan untuk pengasingan, penilaian dan 
pengeluaran antibodi.  Dalam kajian ini, kami berjaya untuk mereka bentuk buku asas 
tertentu untuk anti-HIV1-CA scFv, yang telah digunakan dalam PCR penguatan anti-HIV1-
CA scFv, MBP dan pMXB10Hp24-6His vektor. Selepas itu, analisis enzim sekatan telah 
dilakukan dengan menggunakan Nde1-R / Not1-F enzim kemudian memasukkan dan vektor 
terhad telah ligated. The plasmid dibina, pMXB10-MBP-karena justru-scFv46 telah 
dipindahkan ke E.Coli DH5-α sel berwibawa. Banyak klon positif telah dibentangkan di atas 
pinggan yang berubah dan klon telah dipilih secara rawak untuk mengesahkan oleh koloni 
PCR yang menunjukkan dengan jelas band untuk pMXB10-MBP-karena justru-scFv46. 
          The plasmid DNA telah dituai, disucikan kemudian berubah menjadi NiCo21 (DE3), 
Shuffle (C3029) sel-sel yang mempunyai kebolehan untuk ungkapan protein. Koloni PCR 
telah dilakukan untuk mengesahkan kehadiran klon pMXB10-MBP-karena justru-scFv46 
dalam transformant itu. Kultur pemula telah disediakan untuk mengoptimumkan ungkapan 
protein kepentingan; (NiCo21-TEVEco dan SHUFFLE-TEVEco) sel-sel yang berwibawa 
XX 
 
telah digunakan. Menariknya, NiCo21-TEVEco menunjukkan Overexpressed MBP-scFv-46 
protein Hgabungan adalah terutamanya hadir dalam pecahan tidak larut. Analisis 
Immunoblot dengan antibodi anti-6His mendedahkan bahawa tiada MBP-scFv-46 protein 
hadir dalam pecahan larut; Walau bagaimanapun, hampir 90% -95% daripada protein 
gabungan MBP-scFv telah melekang oleh protease karena justru menggunakan SHUFFLE-
TEVEco. Analisis Immunoblot juga menunjukkan bahawa hampir 40% daripada scFv hadir 
dalam pecahan larut, yang bermakna kita berjaya untuk membangunkan sistem baru bagi 
mencapai Kawalan dalam pemprosesan vivo MBP-scFv protein gabungan: Ke arah 
pengeluaran yang tinggi larut scFv dari E.Coli. 
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CHAPTER 1 
INTRODUCTION 
1.1 Epidemiology and Origin of HIV 
           Acquired Immunodeficiency Syndrome (AIDS) is one of the most serious 
diseases worldwide (Leeper and Reddi, 2010), it is caused by Human Immune 
deficiency Virus (HIV) (Sierra et al., 2005;Sarngadharan et al., 1984). 
             Estimating number of people living with HIV is 35.3 million in 2012 
(UNAIDS,2013), wide separation of HIV with huge percent in middle and low-
income countries lead to approximately 2 million infected patients dead every year.  
Of note, the highest percent of HIV in the world comes from sub-Sahara Africa with 
almost 67% of total world infections (UNAIDS, 2013). 
           Obviously, HIV-1 is transmitted from animals to humans especially from 
West and Central Africa (Hemelaar, 2012).  HIV can be classified in two main types; 
firstly: HIV-1 and its related groups M, N, O and P and the second type: HIV-2 
which has A-H group.  HIV-1 are more prevalent and highly infective comparing to 
HIV-2 (Hemelaar, 2012). 
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1.2 Structure of HIV 
             Great efforts have been done to control AIDS epidemic through studying the 
biology, biochemistry and structural biology of HIV in order to understand the 
interaction between drugs and viral component (Turner and Summers, 1999). 
             HIV is a member of lentivirus genus which includes retrovirus species with 
complex genome.  HIV’s genome is encoded by RNA which converts to viral DNA 
when entering new host cell by viral reverse transcriptase (RT) (Ganser-Pornillos et 
al., 2008). HIV causes infection and destruction of CD4+ lymphocytes with in half-
life of two days (Perelson et al., 1995). 
          Lentivirus spices, which composed of enveloped lipid bilayer derived from 
membrane of the host cell (Ganser-Pornillos et al., 2007). External surface 
glycoprotein (gp 120) are fixed to virus via interaction with transmembrane protein 
(gp41)(Ganser-Pornillos et al., 2007). Additionally the lipid bilayer may also contain 
some cellular membrane protein like actin, ubiquitin and major histocompatibility 
antigen (Arthur et al, 1992). The Matrix shell composed of around 2000 copies of 
matrix protein (P17) which lies in the inner surface of membrane of the virone, and 
the capsid core part ca. (P24) which composed of around 2000 copies of capsid 
protein and lies in the middle of the virus (Figure 1.2).  Also, it includes 
nucleocapsid (P7) and three essential virally encoded enzyme Reverse Transcriptase 
(RT), Integrase(IN) and Protease(PT)(Turner and Summers,1999). 
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Figure 1.2. Structure of the mature HIV virion. 
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1.3 Mode of Transmission 
HIV is transmitted mainly through three routes.  Firstly, from mother to child 
which may be during pregnancy, delivery or breastfeeding (Vertical transmission). 
Secondly, through exposure to infected body or fluid, third route through sexual 
contact either homosexual or heterosexual (Markowitz, 2007). In addition ,there are 
links between HIV subtypes and transmission routes, a recent study which had been 
done in Uganda showed that the subtype D has lower rate of heterosexual 
transmission than subtype A.  In addition, the subtype B infection can be constantly 
associated with intravenous drug abuse across the world (Hemelaar, 2013). The 
transmission route in America, Europe and Australia is mainly by heterosexual route 
which is associated with non B subtype and believed to be originated from Africa 
and Asia immigrants (G.Yebra et al, 2009).  In India and Southern Africa, it is 
almost unique in subtype C to be caused from heterosexual transmission 
(C.Williamson, 1995). Of note, one of the transmission routes is mother-to-child 
transmission (MTCT), which had been shown in two large studies in Kenya and 
Uganda, the subtypes A and subtype D has higher rate of (MTCT) with no 
significant difference between them (Eshleman SH, et al.,2005; Murray MC et al., 
2000 ). 
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1.4 Pathophysiology of HIV 
         Briefly, once the virus enters the body, it starts replication and killing T helper 
cells which plays an important role in adaptive immune response (Piatak,et al., 1993).  
An initial period of influenza like illness, with seroconversion then the patient develops 
the second stage which called asymptomatic infection or latent period that is 
characterized by falling of CD4 lymphocyte count to be less than 200 cells/ml of blood 
(Pantaleo G. et al., 1997).  After a short period of time, the symptomatic stage of the 
disease begins, followed by AIDS caused by depletion of CD4+ T cells which allows the 
opportunistic infection to attack the body without any defense leading to death at the end 
(Hel Z. et al, 2006). 
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1.5 Diagnosis of HIV 
           HIV/AIDS is diagnosed normally by laboratory testing as majority of patient 
develop seroconvert or specific antibody within three to twelve weeks of initial infection 
(CDC. 2012).  Before antibody production it can be detected through HIV-RNA or P24 
antigen, the positive result from both tests and for children especially below 18 months 
can be confirmed by PCR (CDC. 2012).  For classification of HIV there are two main 
staging systems to use, either CDC classification system for HIV infection or WHO 
disease staging system for HIV infection and disease.  The CDC system is more 
frequently used in developed countries.  The center for disease, control and prevention 
(CDC) updated this system of classification in 2014, which rely on CD4 count and 
clinical symptoms for those patients older than 6 years (CDC. 2014). 
 Stage 0: the time between a negative or indeterminate HIV test followed less than 180 
days by a positive test. 
 Stage 1: CD4 count ≥ 500 cells/µl and no AIDS defining conditions. 
 Stage 2: CD4 count 200 to 500 cells/µl and no AIDS defining conditions. 
 Stage 3: CD4 count ≤ 200 cells/µl or AIDS defining conditions. 
 Unknown: if insufficient information is available to make any of the above 
classifications. 
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1.6 Prevention and Control 
            Firstly, form mothers to child (MTCT) or vertical transmission, there are 
programs to prevent this route which have shown great reduction in rate of transmission 
with approximately 92-99 %,( Horvath, T,et al.,2009). Those programs include using of 
antiretroviral during pregnancy and after delivery and switching breastfeeding to bottle 
feeding if it’s convenient (Siegfried, N, et al., 2011). 
           Secondly, prevention of sexual contact by using condom, this has caused 
reduction of transmission rate by 80% (Crosby, R. et al., 2012).  Also, both WHO and 
UNAIDS recommended male-circumcision as studies showed that it can reduce the rate 
of transmission of HIV by 38-66% (Siegfried, N.et al., 2009). 
         Finally, HIV patients whose CD4 count ≥ 350cells/µL can be treated with 
antiretroviral. This can protect 96% of their partner from infection (Chou R.et al., 2012). 
In addition, post exposure prophylaxis (PEP) can be controlled by a course of 
antiretroviral therapy within 48-72 hours after exposure to HIV positive patient or blood 
or genital secretion (Kuhar DT.et al., 2013). 
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1.7 Treatment of HIV 
            Indeed, up till now there are no treatment for HIV/AIDS which can eradicate the 
virus totally, although we have (ART) since 30 years (Chhatbar et al., 2011). Highly active 
antiretroviral therapy (HAART) works mainly through decreasing the virus progression and 
controlling its replication (Tab. 1.7).  Also, it delays the progression of immunodeficiency 
which subsequently increases the life expectancy of the AIDS patients and decreases death 
rates (Broder, 2010; Chhatbar et al., 2011).  Noteworthy, it’s estimated that in developed 
countries and high-income ones like USA, (HIV-1) infected patients can live 14 years longer 
than expected if he/she continue on antiretroviral drug (Walensky et al., 2006; Vermund, 
2006). 
          The basic antiretroviral drug and the first one ever was azidothymidine (AZT), which 
is nucleoside reverse transcriptase inhibitor (NRTIs) ( Broder, 1990), after a period of time a 
new member of non-nucleoside reverse transcriptase inhibitor  (NNRTIs) has joined 
(NRTIs) in order  to attack HIV-1 RT site (Broder, 2010). Moreover, viral protease 
inhibitors were developed, besides a range of drugs which target different phases of viral 
replication process; like inhibition of early entry through  fusion inhibition step using gp41 
antagonist  (Kilby et al., 1998), or even more earlier  through blocking CCR5 co-receptor 
(Kuritzkes, 2009). 
            Although highly active antiretroviral therapy (HAART) is a good tool which convert 
(HIV-1) infection into chronic manageable disease, it is believed that (HAART) has a 
secondary side effect especially with aged patients under chronic treatment with (HAART) 
(Esté and Cihlar, 2010).  Indeed, there are a lot of challenges regarding available regimen of 
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(HAART) as lack of efficacy, toxicity and incompatibility with other essential medications 
(Esté and Cihlar, 2010), so it is needed to find new tools to overcome these problems. 
 
 
Tab. 1.7 Approved antiretroviral drugs.Adapted from: Drugs Used in the Treatment of HIV 
Infection, U.S. FDA. Drugs are listed in order of FDA approval within each class 
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1.8 Antibody and Antibody fragments (scFv) 
           Antibody is believed to protect the body against different types of infections and it is 
a naturally defense mechanism which has the ability to protect or even totally prevent the 
infection (Shukra et al., 2014).  Antibodies were firstly discovered by Behring and Kitasato 
at 1983, where they found that infected animal can provide immunity against diphtheria, 
later on the door opened for the antibody production for Human therapy (Shukra et al., 
2014). Eventually, immune sera from sheep, chickens, horses and humans can be collected 
and used as a treatment for some infectious diseases like, pneumococcal pneumonia, 
diphtheria and Tetanus (Casadevall A et al, 1994: Casadevall A, 1999). 
             Antibodies are found on the surface of B cells and extracellular fluids which can be 
used by the immune system to damage or kill bacteria or viruses (Sanz, L. et al. 2005).  The 
basic unit of antibody is one immunoglobulin G (IgG) unit and compose of four chains, two 
identical light chains (L) and two identical heavy chains (H) with a molecular weight 150 
KD ( Nuñez-Prado et al. 2015). 
             Nowadays one of the most useful tools in research, diagnosis and therapy is 
Monoclonal antibodies (mAbs) (Sanz, L. et al. 2005). Obviously, by using molecular 
engineering technologies we can easily produce small and at the same time functional 
antibody. The single-chain variable fragments (scFv) contain both heavy chain (VH) and 
light chain (VL) which connected to each other by a flexible linker (Hagemeyer CE. 2009). 
The single-chain variable fragments (scFv) can be produced either in Eukaryote or 
prokaryote; however bacterial system is by far the best option regarding the good yield and 
low cost (Michael Steinitz, 2014). 
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             Indeed,  reducing condition of the E-coli bacterial cytoplasm make it difficult to 
form soluble scFv due to inability to form disulfide bond, however  scFv can be produced 
either in periplasm or  produced in cytoplasm  as insoluble inclusion bodies that go further 
for a refolding process.  In addition to that expression of scFv as a C-terminal fusion to 
maltose binding protein (MBP) can lead to high level production of stable and functional 
fusion protein. 
1.9 Prokaryotic system 
Recombinant Technology is one of the important tools in order to obtain a cheap, highly 
yielded and easily purified protein. The cheapest host that can be used is Escherichia Coli 
because it has different strains and produce good quantity of desired protein; however in 
many situations E-Coli can lead to production of insoluble and by default nonfunctional 
proteins (Vaks and Benhar, 2014). Soluble proteins can be obtained from recombinant E-
Coli, by making some modification through engineering of target; like fusion tag 
technology. 
In order to achieve soluble protein expression in E.coli cytoplasm, refolding of the 
inclusion bodies and purification process is quiet difficult and expensive comparing to 
purifying the highly expressed soluble protein (Vaks and Benhar, 2014). Therefore the best 
way is to produce a recombinant protein in a soluble form than to proceed with in vitro 
method. One of the good modification tools is reduction of temperature as aggregation 
reaction depends mainly on temperature, in addition the activity of some E-Coli chaperones 
have been increased on temperature around 300C, but the sudden decrease in temperature 
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can lead to inhibition of replication, transcriptional and finally translation. Also, low 
induction level can lead to higher amount of soluble protein (Vaks and Benhar, 2014). 
1.10 Objective of this study 
Main objective 
To establish controlled intracellular processing of MBP-scFv in TEVEco system for the 
production of functional scFv. 
Specific objectives 
1. To clone anti-HIV1-CA scFv gene with MBP as fusion partner in pSA expression 
vector. 
2. To optimize expression of MBP-anti-HIV1-CA-scFv and its  controlled intracellular 
processing in TEVEco 
3. To characterize the purified anti-HIV1-CA-scFv. 
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CHAPTER II 
MATERIALS AND METHODS 
2.1 PCR amplification of both MBP-TEV using pRK793 plasmid and amplification of 
anti-HIV1-CA scFv using pHEN2 Ril-scFv46: 
       The PCR amplification was performed in order to amplify the MBP-TEV and anti-
HIV1-CA scFv using specific primers. The PCR reactions were consisted of 5 X KAPA 
HiFi buffer, 2mM of Magnesium Chloride, mixture of dNTPs (0.3mM), and 10 ng of 
template DNA. 0.3 µM of forward and reverse primers.1X KAPA HiFi DNA polymerase. 
The PCR reaction was assembled on ice as following: 
Component Volume (µL) 
5X KAPA HiFi buffer(1X) 10 
dNTPs(0.2 mM) 1.5 
Forward and reverse Primers(0.3 µM each) 3 
Template DNA(10 ng) 2 
KAPA HiFi DNA polymerase(1 U) 1 
PCR water 32.5 
Total 50 
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Tab. 2.1.1: PCR component for amplification of both MBP-TEV and amplification of anti-
HIV1-CA scFv. 
        The contents of PCR tubes were vortexed followed by a brief spin using a 
microcentrifuge. The PCR tubes were then transformed to the thermocycler and cycling 
condition as follows:  Initial denaturation at 95ºC for 3 minutes;10 cycles of (i) denaturation 
at 98 ºC for 20 seconds,(ii) annealing temperature of 65-55ºC for 15 seconds, (iii) extension 
at 72 ºC for 1 minute.  This was followed by 25 cycles of denaturation at 98 ºC for 20 
seconds at annealing temperature of 55 ºC for 15 seconds and final extension at 72 ºC for 5 
minutes.  The PCR amplified product underwent electrophoresis on 1% agarose gel and then 
visualized by placing into the gel documentation system (Chemiluminescence, 
VilberLourant) and the gel image was captured. 
Primers used: 
Primer Template Amplicon size(Kb) 
MBP-NdeI-F1 pRK 793 1.2 
TEV-SfiI-R1 
scFv-SfiI-F1 PHEN2-Ril-scFv-46 0.75 
scFv-NotI-R1 
 
Tab.2.1.2 Primers used for amplification of both MBP-TEV and amplification of anti-HIV1-
CA scFv. 
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1% Agarose Gel Electrophoresis: 
1% agarose gel was prepared by adding 0.35 gram of agarose in 35 ml of 1 X Tris 
Acetic Acid EDTA (TAE) buffer.  The solution was left for 5 minutes then heated at 50 
level powers in a microwave oven for 1 minute to mix agarose until completely dissolved.  
The dissolved solution was cooled down until temperature equilibrated.   Ethidium bromide 
was added into the agrose flask to a final concentration of 0.01mg/ml and the contents were 
mixed by gentle swirl. The gel casted by pouring 35 ml of agarose solution into the gel 
casting mold immediately followed by the insertion of sample loading comb.   The gel was 
allowed to polymerize by setting it for 30 minutes at room temperature, then it was 
transferred to the electrophoresis unit.  This was followed by adding 1 X TAE buffer 
followed by the removal of comb.  Preparation of sample were done as follow: 1µl of DNA 
sample was mixed with 1µl of 6 X loading dye in addition to 4 µl of TAE buffer which was 
loaded in wells using micropipete.  1 µl of molecular weight markers (1Kb DNA Ladder of 
New England BioLab) + 1 µl 6 X loading dye + 4 µl of TAE buffer were also loaded 
simultaneously in the gel.  The electrophoresis was carried out at 110 volts for 35 minutes, 
then DNA was visualized by placing into the gel documentation system 
(Chemiluminescence, VilberLourant) and the gel image was captured. 
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2.2-Clean-up for both anti-HIV-1 CA-scFv46 and MBP-TEV using SYBRE safe 
gel: 
         1% agarose gel was prepared by adding 0.35 gram of agarose in 35 ml of 1 X Tris 
Acetic Acid EDTA (TAE) buffer.  The solution was left for 5 minutes then heated at 
50 level powers in a microwave oven for 1 minute to mix agarose until completely 
dissolved.  The dissolved solution was cooled down until the temperature 
equilibrated. 17.5µl of Sybre safe was added into the agrose to a final concentration 
and then contents were mixed by gentle swirl.  The gel was casted by pouring 35 ml 
of agarose solution into the gel casting mold followed by the insertion of sample 
loading comb.  The gel was then allowed to set for 30 minutes at 4ºC and covered. 
Then the gel was transferred to electrophoresis unit where 1 X TAE buffer was 
added, followed by the removal of comb. 50µl of DNA sample was mixed with 10µl 
of 6 X loading dye and carefully loaded into the wells using a micropipette.  1 µl of 
molecular weight markers (1kb DNA Ladder of New England BioLab) were also 
loaded simultaneously in the gel. The electrophoresis was carried out at 80 volts for 
50 minutes.  The DNA was visualized by placing into the gel documentation system 
(Chemiluminescence, VilberLourant) and the gel image was captured.   
Subsequently, the gel band of interest was cut using aseptic cutter under U.V light.  
2ml tube was prepared and weighted before and after putting the gel, then it was 
spined for 13000xg for 1 minute, followed by dissolving the gel using block heater 
unit at 58ºC.  The weight of the gel after dissolving was 383mg; subsequently the 
same amount of membrane binding solution was added, and then was put in block 
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heater for 2 minutes and vortexed, the last step was repeated 3 times.  1% agrose gel 
was put in 25ml TAE buffer. 
2.3  Ligation process for insert MBP-TEV and anti-HIV1-CA scFv: 
       The MBP-TEV ration: to anti-HIV1-CA scFv was 1:1 for the most efficient 
ligation depends on the DNA concentration, the ligation mixture was set on ice. The 
ligation mixture was prepared as shown in this table: 
Component Volume(µl) 
Restricted DNA(MBP-TEV) insert 100ng 1 
Restricted DNA(anti-HIV1-CA scFv) 
insert 100ng 
1 
T4 DNA ligase buffer (10x) 1 
T4 DNA ligase 1 
dH2O 6 
Total 10 
 
Tab.2.3: Component of ligation Mix 
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The ligation mixture was prepared by vortexing then was spun in a microcentrifuge. 
Subsequently the ligation mixture was set in thermocycler and temperature was adjusted 
as follow: 
Cycles =   99 
10ºC/30 sec 
11ºC/30 sec 
12ºC/30 sec 
13ºC/30 sec 
14ºC/30 sec 
15ºC/30 sec 
16ºC/30 sec 
17ºC/30 sec 
18ºC/30 sec 
End cycle 
24ºC/ 2hr 
Storage /pause/4ºC. 
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2.4 PCR amplification for insert MBP-TEV-anti-HIV1-CA scFv: 
          The PCR amplification was performed in order to amplify MBP-TEV- anti-HIV1-CA 
scFv using specific primers. The PCR reactions consisted of 5 X KAPA HiFi buffer, mixture 
of dNTPs (0.3 mM) and 10 ng of template DNA.  0.3 µM of forward and reverse primers. 
1X KAPA HiFi DNA polymerase. The PCR reaction was assembled on ice as follow: 
 
Component Volume (µL) 
5X KAPA HiFi buffer(1X) 10 
dNTPs(0.3mM) 1.5 
Forward and reverse Primers(0.3µM each) 3 
Template(10ng) 1 
1X KAPA HiFi DNA polymerase(1 U) 1 
PCR water 33.5 
Total 50 
 
Tab.2.4.1: Component for PCR amplification for MBP-TEV-anti-HIV1-CA scFv 
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 The contents of PCR tubes were vortexed followed by a brief spin using a 
microcentrifuge. The PCR tubes were then transformed to the thermocycler and cycling 
condition as follow: 
Initial denaturation at 95ºC for 3 minutes;10 cycles of (i) denaturation at 98 ºC for 20 
seconds,(ii) annealing temperature of 65-55ºC for 15 seconds, (iii) extension at 72 ºC for 1 
minute.   This was followed by 25 cycles of denaturation at 98 ºC for 20 seconds at 
annealing temperature of 55 ºC for 15 seconds and final extension at 72 ºC for 2 minutes. 
The PCR amplified product was electrophoretically on 0.7% agrose gel and then visualized. 
Primers used: 
Primer Template Amplicon size(Kb) 
MBP-NdeI-F1 MBP-TEV-anti-HIV1-CA 
scFv 
1.95 Kb 
scFv-NotI-R1 
 
Tab.2.4.2: Primers used for PCR amplification for insert MBP-TEV-anti-HIV1-CA scFv 
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2. 5 PCR amplification of (pSA) vector using pMXB10-HP24-6His: 
         The PCR amplification was performed in order to amplify (pSA) vector using specific 
primers. The PCR reactions consisted of 5 X KAPA HiFi buffer, mixture of dNTPs (0.3 
mM), and 10 ng of template DNA. 0.3 µM of forward and reverse primers.1X KAPA HiFi 
DNA polymerase. The PCR reaction was assembled on ice as follow: 
Component Volume (µL) 
5X KAPA HiFi buffer (1X) 10 
dNTPs(0.3mM) 1.5 
Forward and reverse Primers(0.3µM each) 3 
Template(10ng) 3 
1X KAPA HiFi DNA polymerase (1 U) 1 
PCR water 31.5 
Total 50 
 
Tab.2.5.1: Component for PCR amplification of (pSA) vector 
The contents of PCR tubes were vortexed followed by a brief spin using a microcentrifuge. 
The PCR tubes were then transformed to the thermocycler and cycling condition as follow: 
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        Initial denaturation at 95ºC for 3 minutes;10 cycles of (i) denaturation at 98 ºC for 20 
seconds,(ii) annealing temperature of 65-55ºC for 15 seconds, (iii) extension at 72 ºC for 1 
minute.  This was followed by 25 cycles of denaturation at 98 ºC for 20 seconds at annealing 
temperature of 55 ºC for 15 seconds and final extension at 72 ºC for 2 minutes. The PCR 
amplified products were electrophoretically on 0.7% agrose gel and then it was visualized. 
Primers used: 
Primer Template Amplicon size(Kb) 
6 His-Not1-F1 pMXB10-HP24-6His 5.3Kb 
pMXB10-Nde1-R1 
 
Tab.2.5.2: Primers used for PCR amplification of (pSA) vector 
 
2.6, 2.7 Purification and Gel clean-up for insert MBP-TEV-anti-HIV1-CA scFv46, and 
(pSA) vector, using Wizarad PCR Clean-up system: 
Binding of DNA: 
This was done using the same amount of membrane binding solution (50 µl) equal to 
the amount of PCR product (50 µl), SV minicolumn was inserted into collection tube, then 
the prepared PCR product was transferred to the minicolumn assembly and incubated for 1 
minute, then it was centrifuged at 13000 xg for 1 minute, the precipitate was taken and 
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reload into Minicolumn assembly tube, then incubated for 1 minute and centrifuged at 
13000 xg for 1 minute, the last step was repeated 2 times. 
Washing: 
700 µl membrane wash solution (ethanol) was added.  Incubation was done for 1 
minute then the mixture was centrifuged for another 1 minute at 13000 xg. then discard the 
flow through and reinsert Minicolumn into collection tube . Another 500 µl of Membrane 
Wash Solution was added and centrifuged at 13000 xg for 5 minutes; recentrifugation was 
done for 1 minute after discard the flowthrough. 
Elution: 
Minicolumn was carefully transferred to a clean 1.5 ml microcentrifuge tube, 10 µl 
of Nuclease free water was added to the Minicolumn, and then incubated for 1 minute and 
centrifuged at 13000 xg for 1 minute. Then last step was repeated 2 times.  Finally the 
Minicolumn was discarded and DNA was stored at 4º C. 
1% agarose gel was run after purification process, then proceed with 0.7% Sybre free 
gel in 50 ml (TAE), using 25µl of Sybre free, subsequently the specific band was cut and the 
clean-up process was continued as mentioned above. 
2.8 Restriction digestion for both insert MBP-TEV-anti-HIV1-CA scFv and vector 
(pSA): 
Restriction digestion for both insert and vector by preparing following component: 
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Component Volume (µL) 
Cut smart buffer(10X) 5 
DNA(1µg) 21 
Nde1 5U/µl 1 
Not1 5U/µl 1 
PCR water 22 
Total 50 
                     
Tab.2.8.1: Component for restriction digestion for both insert and vector 
The contents of PCR tubes were vortexed followed by a brief spin using a 
microcentrifuge. The PCR tubes were then transformed to the thermocycler and cycling 
condition was done at 37ºC for 8hr, and then storage was done at 4ºC. 
Primer Template 
Not1 pMXB10-HP24-6His 
Nde1 MBP-TEV-anti-CA-scFv46 
 
                 Tab.2.8.2: Primers used for restriction digestion for both insert and vector 
